跨矢状窦脑膜瘤术中矢状窦的处理

目的总结跨矢状窦脑膜瘤术中矢状窦的处理方法.方法对26例跨矢状窦脑膜瘤及受累矢状窦进行切除,依具体情况重建或不重建矢状窦.结果该组病人无手术死亡,手术后均未加重原有神经功能障碍,无脑血液回流障碍,7例重建矢状窦者未发现有矢状窦内血栓形成.结论矢状窦旁脑膜瘤的治疗除肿瘤切除外,对受累上矢状窦处理是否彻底对预防术后复发是至关重要的.对受累矢状窦应按具体情况按一定的原则进行积极处理.     

89例小脑幕脑膜瘤的显微外科手术治疗

目的 总结小脑幕脑膜瘤的手术治疗经验。方法 回顾分析1993年5月-2006年5月，89例经手术治疗的小脑幕脑膜瘤病人的临床表现、影像学检查、手术记录、病理及术后早期并发症。常见症状是头痛（54例，60．7％）、头晕（29例，32．6％）、步态异常（34例，38．2％）、听力损害（27例，30．3％）及面部疼痛（20例，22．5％）。主要体征是共济失调（38例，42．7％）、运动和感觉障碍（31例，34．8％）及脑神经损害（48例，53．9％）。多数病例MRI表现为等T1、T2信号并明显均一强化。结果 本组全切除65例（73．0％），次全切除23例（Okudera-KobayashiⅣ—Ⅴ级）。手术并发症的发生率和病死率分别为22．5％和1．1％。结论 根据小脑幕脑膜瘤部位以及与周围神经血管关系选择最佳手术入路。如全切肿瘤可能带来重要的神经功能损害，应考虑残留部分肿瘤。     

神经内镜辅助眶上锁孔入路治疗巨大嗅沟脑膜瘤

目的探讨神经内镜辅助眶上锁孔入路治疗巨大嗅沟脑膜瘤的手术效果及手术技巧。方法采用内镜辅助、眶上锁孔入路（显微手术）治疗12例巨大（≥7cm）嗅沟脑膜瘤。结果肿瘤全切除9例（SimpsonⅠ级切除5例，Ⅱ级切除4例），次全切除（SimpsonⅢ级切除）3例。无手术死亡。10例随访3个月～2年，平均14个月。9例恢复正常生活，1例生活能自理。NRI随访9例，肿瘤无复发。结论利用神经内镜辅助及显微外科技术，采用眶上锁孔入路、对肿瘤进行分块切除治疗巨大嗅沟脑膜瘤，手术创伤小，疗效满意。     

嗅沟脑膜瘤术式选择及长期临床预后随访

目的分析嗅沟脑膜瘤的手术治疗和随访结果。方法收集20例嗅沟脑膜瘤手术病例,并分析其临床表现及随访结果。结果嗅沟脑膜瘤大多以精神症状、视觉障碍和嗅觉减退为首发症状,9例行冠状切口,4例行半冠状切口,分块切除肿瘤,5例翼点入路,1例纵裂入路。1例眶上入路,SimpsonI级切除6例。SimpsonⅡ级切除13例,SimpsonⅢ级切除1例,预后良好,1例复发。随访时间1~6年(平均3.1年),术前术后均保留嗅觉的为2例,精神状态改善18(91%)和视力障碍改善的15(75%)。1例(5%)复发再次手术。结论术式的选择取决诸多因素,预后取决于手术中的组织保护。     

Potential doubling time and tumour doubling time in meningiomas and neurinomas

Summary Cell kinetic study plays an important role in treatment planning of brain tumour patients. MIB-1 antibody has recently become available, which detects Ki-67 antigen even in the formalin-fixed paraffin-embedded specimens. We performed MIB-1 immunostaining in 50 meningiomas and 50 neurinomas, and estimated the cell cycle time (tc) and potential doubling time (Tpot) from MIB-1 staining index (MIB-1 SI) and mitotic index (MI). MIB-1 SI logarithmically correlated with MI in both meningiomas and neurinomas. The tc and the Tpot were expressed as a function of the mitosis time (tm), while the tm is known to be around one hour and not exceeding two hours. When the tm was assumed to be one hour, the average tcs of meningiomas and neurinomas were 6.53±3.56 days and 7.67±3.27 days, respectively. The Tpots were447 × (MIB-1 SI)^–1.29 × tm in meningiomas, and490 × (MIB-1 SI) ^–0.98 × tm in neurinomas.The tumour doubling times (Tds) were calculated from serial imaging studies in 22 neurinomas and 15 meningiomas. The Tds were formulated as794 × (MIB-1 SI) ^–0.83 in meningiomas and1380 × (MIB-1 SI) ^–0.97 in neurinomas. Most of the Tds correlated well with the Tpots in meningiomas and neurinomas, and exceeded values of the Tpot when the tm is assumed to be one hour, although a few tumours showed unexpectedly longer Tds. The Tpot and the tc estimated from MIB-1 SI and MI are clinically useful parameters for predicting the growth potential of meningiomas and neurinomas where no other simple methods are available.     

脑膜瘤瘤周脑水肿

对经手术病理证实，ＣＴ资料完善的１１４例脑膜瘤进行回顾性分析，研究脑膜瘤的部位、大小、组织学类型及其它的生物学特性与瘤周水肿的相关性。通过ＣＴ确定瘤周水肿的有无及程度，对各种参数采用χ２、秩和等统计学检验方法进行分析。脑膜瘤瘤周水肿的发生与肿瘤的病理组织学类型有关，而与肿瘤的大小、钙化、病人的年龄和性别无关，上皮型、血管型及恶性脑膜瘤较其它组织学类型更易发生瘤周水肿。颅内压增高与瘤周水肿的发生密切相关，矢状窦旁、大脑凸面、镰旁、蝶骨嵴、前颅窝及嗅沟部脑膜瘤较幕下及其它部位脑膜瘤易发生瘤周脑水肿，但上述各部位间瘤周水肿的发生率比较无统计学差异。性别、年龄、病程与瘤周水肿的发生无关     

Mdm2、Bc1-2、AR在良性脑膜瘤中表达的关系

目的研究凋亡相关蛋白mdm2、bcl-2和AR（雄激素受体）之间的关系，为脑膜瘤的性激素对抗治疗提供一些新信息。方法从华西医院病理科获得04年1月-07年12月病理诊断明确的脑膜瘤共394例，计算机随机抽样60例，其中良性脑膜瘤（WH0I）41例，用LsAB法做免疫组化染色，检测mdm2、bcl-2、AR的表达。结果在良性脑膜瘤中mdm2、bcl-2、AR的表达率分别为67％、62％、33％，三者之间没有相关关系。结论（1）是否能够作为抗性激素治疗疗效的筛选和／或预测指标，bcl-2比mdm2更有潜在价值。（2）AR在脑膜瘤中的促进生长作用的相对独立性，提示AR可以作为脑膜瘤对抗激素治疗的新靶点进一步研究。     

Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas

Meningiomas are usually benign tumors; however, they can recur after surgical resection and occasionally show histological progression to a higher malignancy grade. Five such rare cases of aggressively recurring meningiomas were present in our departmental cohort of 923 primary meningeal neoplasms operated over a 17-year period. Four other aggressively recurring meningeal tumors with a very similar clinical and histomorphological appearance (three undifferentiated meningeal sarcomas, one hemangiopericytoma) were also included in this study. We investigated whether disease progression can be traced by genetic alterations and whether a pattern of genetic alterations is specific for meningiomas. A total of 40 specimens from primary tumors and multiple recurrences of the nine patients were analyzed with 26 polymorphic allelic markers for deletions on 1p, 1q, 9q, 10q, 14q, and 22q. Loss of heterozygosity (LOH) at 22q was observed in all meningiomas cases at the earliest time point analyzed. Allelic loss at 1p was seen in the original tumor in two cases and upon meningioma recurrence in two others. Deletion on 10q occurred during tumor progression in two cases, and on 9q and 14q in one case. While allelic loss at 22q appears to be an early event in aggressive meningioma disease, there is a clear correlation of further deletions on chromosome arms 1p, 9q, 10q, and 14q with histopathological and clinical progression, as shown in these intraindividual trackings. None of these genetic findings were present in the non-meningiomatous meningeal tumors, indicating that meningothelial cells have their own lineage-specific genetic pathways towards clinical malignancy.     

Neoplasms involving the central nervous system in the older old

Geriatric cancer patients present special challenges for clinicians. Few large series have been published in the last 20 years on the types of neoplasms that involve the central nervous system (CNS) in older individuals. To review types of neoplasms involving the central CNS that are currently being encountered by pathologists and neurosurgeons, we identified from our databases for the years 1992-2002, inclusive, patients 75 years or older who had symptomatic lesions requiring neurosurgical interventions. Retrospective characterization of tumors by immunohistochemistry, in situ hybridization, and fluorescence in situ hybridization was performed whenever possible and relevant to tumor type. Neurosurgical procedures (n=125) on 119 patients were identified; 90 patients were diagnosed as having neoplasms, with clot evacuation or infections being the most frequent non-neoplastic conditions necessitating surgery. Tumor types included glioblastomas (36 patients), meningiomas (16), pituitary adenomas (12), lymphomas or other hematological malignancies (8), anaplastic gliomas (5), metastases (6), head and neck malignancies with direct intracranial extension (3), and other miscellaneous tumor types (4). Compared with older literature series, we encountered a larger number of elderly patients with CNS lymphomas and fewer who came to surgery for CNS metastatic disease. In the "older old", glioblastomas are the most frequent symptomatic tumors necessitating surgical intervention. Glioblastomas in this aged cohort display the signature features of the small cell phenotype (62%), high cell cycle labeling indices (mean MIB-1-labeling index=25.1%), and either amplification of epidermal growth factor receptor or gain of chromosome 7 by fluorescence in situ hybridization (93% of assessable cases).     

脊索样脑膜瘤临床病理分析

目的：研究脊索样脑膜瘤的临床与病理特征,以提高其早期诊断率。方法：运用组织病理学及免疫组化标记（Ｓ－Ｐ法）对３例脊索样脑膜瘤进行临床病理学和组化（ＰＡＳ）、免疫组化（ＥＭＡ、Ｖｉｍ、Ｓ－１００、ＣＫ）及电镜观察。结果：组织学瘤细胞胞浆内外均见粘液,在粘液基质背景中有成簇或成行的类液滴样细胞,瘤组织中有典型的脑膜上皮漩涡结构,组化及免疫组化示ＰＡＳ（＋）、ＥＭＡ（＋）、Ｖｉｍ（＋）、Ｓ－１００（＋）